Time

Topic

Speaker

Moderator: Josh Simmons, MD, FACP

7:30 AM

Welcome and Day Overview

• Sagar Lonial, MD, FACP
• Suresh Ramalingam, MD, FASCO

Breast Cancer

7:40 AM

Omission of Surgical Staging of the Axilla in Breast Cancer: When and Why

• Cletus Arciero, MD, FACS

7:55 AM

DEBATE
Is PMRT Needed in Patients with Nodal pCR Following Neoadjuvant Chemotherapy?

• Reshma Jagsi, MD, DPhil
• vs
• Mylin Torres, MD

8:15 AM

Treatment Approaches after CDK4/6 Inhibition in HR+/HER2-Negative MBC

• Kevin Kalinsky, MD, MS

8:30 AM

Optimizing ADCs in HER2-Negative Breast Cancer

• Manali Bhave, MD

8:45 AM

DEBATE
Is There Still a Role for Anthracycline in Early Stage Breast Cancer?

• Ruth Sacks, MD
• vs
• Jade Jones, MD

9:05 AM

Immunotherapy in Operable Breast Cancer

• Jane Lowe Meisel, MD

9:20 AM

Patient-Based Panel Discussion with ASCO Highlights and Q&A

• All speakers

9:40 AM

Break

Head and Neck

10:10 AM

Improving the Standard in Locally Advanced SCCHN: An Elusive or Delayed Reality?

• Nabil Saba, MD, FACP

10:25 AM

DEBATE
Surgical Resection Without Pre-Op Immunotherapy is the Preferred Therapeutic Approach for Locally Advanced Skin SCC

• Mark W. El-Deiry, MD, FACS
• vs
• Conor Steuer, MD

10:45 AM

Optimal Management of Thyroid Cancer

• Taofeek Kunle Owonikoko, MD, PhD

Lecture of the Day

11:00 AM

Future Prospects for Cell Therapy in Solid Tumors

• Edmund K. Waller, MD, PhD, FACP

11:20 AM

Lunch

Moderator: Andrew Johnson, MD

Leukemia

12:05 PM

Molecular Testing in Hematologic Malignancies: What Does Every Patient Need at a Minimum?

• David A. Frank, MD, PhD, FACP

12:20 PM

Beyond JAK Inhibition in MPN

• Anthony M. Hunter, MD

12:35 PM

Selection of Initial Therapy for CML

• Colin A. Vale, MD

12:50 PM

Treatment Discontinuation for CML

• Amelia A. Langston, MD

1:05 PM

Treatment Algorithm in the Molecular Era for AML

• William G. Blum, MD

1:20 PM

MDS: How and When to Choose

• Martha Arellano, MD

1:35 PM

Evolving Frontline ALL Therapy: Incorporating Novel BCR-ABL TKIs and Immunotherapies

• Hagop Kantarjian, MD

1:50 PM

Patient-Based Panel Discussion with EHA Highlights and Q&A

• All speakers

2:10 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP

6:00 PM

Welcome Dinner at Beach Club
(Name badges required for entry)

Time

Topic

Speaker

Moderator: Eric Turner, MD

7:30 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FASCO

Brain Cancers

7:35 AM

Immune Therapy for Gliomas – A Path Forward

• Edjah K. Nduom, MD, FAANS

7:50 AM

Radiation for Gliomas – Where Does Proton Therapy Fit In?

• Bree Eaton, MD

Melanoma

8:05 AM

TIL for PD-1-Refractory Melonoma

• Jacob S. Choi, MD, PhD

8:20 AM

Current Management of Melanoma Brain Metastases

• Zachary S. Buchwald, MD, PhD

8:35 AM

DEBATE
Using Pathological Response to Determine De-Escalation of Surgery and Need for Adjuvant Therapy

• Michael Lowe, MD, MA
• vs
• Keith Delman, MD, FACS

8:55 AM

Break

Genitourinary Cancers

9:25 AM

DEBATE
Triplet vs Doublet in M1 Castration-Sensitive Prostate Cancer

• Bassel Nazha, MD, MPH
• vs
• Jordan Ciuro, MD

9:45 AM

PSMA-Targeted Radioligand Therapy in the Management of Prostate Cancer: A Genitourinary Oncologist’s Perspective

• Mehmet Bilen, MD

10:00 AM

Updates in Treatment of Metastatic RCC

• Michael Atkins, MD

10:15 AM

Treatment Updates in Metastatic Urothelial Cancer

• Bradley Carthon, MD, PhD

10:30 AM

Current and Future Directions for NMIBC and MIBC

• Shreyas Joshi, MD, MPH

10:45 AM

Patient-Based Panel Discussion with ASCO Highlights and Q&A

• All speakers

Lecture of the Day

11:05 AM

How Can the Cardio-oncologist Partner with You?
Q&A moderated by Medical Oncology fellow

• Anant Mandawat, MD

11:25 AM

Lunch and Introduction to the Georgia Blood Cancer Trials Network

• Jonathon B. Cohen, MD, MS

Moderator: Gregory Harris, DO, FACOI

Lymphoma

12:05 PM

Recent Changes in the Management of DLBCL

• James O. Armitage, MD

12:20 PM

Integration of Bispecific Antibodies in the Management of Relapsed NHL

• Jason Romancik, MD

12:35 PM

Clinical Advances in the Treatment of CLL

• Susan M. O’Brien, MD

12:50 PM

DEBATE
MRD is an Important Clinical Endpoint in Frontline Management of CLL

• Andres Chang, MD, PhD
• vs
• Jean Koff, MD

1:10 PM

Impact of PTCL Subtype on Selection of Front-Line Treatment

• Mary Jo Lechowicz, MD

1:25 PM

DEBATE
Optimal Management of Advanced Stage HL: Nivo-AVD vs BV-AVD

• Carlos A. Lopez, MD, MPH
• vs
• Pamela Allen, MD, MSc

1:45 PM

Patient-Based Panel Discussion with EHA Highlights and Q&A

• All speakers

2:05 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP

2:30 PM

Georgia Blood Cancer Trials Network Meeting
(Open to all)

• Jonathon B. Cohen, MD, MS

Time

Topic

Speaker

Moderator: Andrew Pippas, MD

8:00 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FASCO

Gastrointestinal Cancers

8:05 AM

DEBATE
Immuno-Oncology in Perioperative Therapy for Early Gastroesophageal Cancer: To Add or Not to Add?

• Oluwadunni Emiloju, MBBS, MS
• vs
• Lindsay Hannan, MD, MSc

8:25 AM

DEBATE
Is First-Line PRRT in GEP-NETs the Standard of Care?

• Daniel M. Halperin, MD
• vs
• Olumide Gbolahan, MBBS, MSc

8:45 AM

DEBATE
Role of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Ready for Prime Time?

• Maria C. Russell, MD
• vs
• Beatrice T.B. Preti, MD, MMEd

9:05 AM

Advances in the Perioperative Management of Early Rectal Cancers

• Olatunji Alese, MD

9:20 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

• All speakers

Lecture of the Day

9:40 AM

Updates in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

• Charles Staley, MD

10:00 AM

Break

Gynecologic Cancers

10:25 AM

Low-Grade Epithelial Ovarian Cancer: Optimizing Targeted and Hormonal Agent Options

• Beryl Manning-Geist, MD

10:40 AM

HER-2/neu-Directed Therapy: Not Just for Breast Cancer Anymore

• Susan Modesitt, MD, FACOG, FACS

10:55 AM

DEBATE
Moving Immunotherapy to the Frontline with Chemoradiation in Locally Advanced Cervical Cancer

• Jill Remick, MD
• vs
• Sarah Dilley, MD, MPH, FACOG

11:15 AM

Dear Investigator Letters: Current Role of PARP Inhibitors in Ovarian Cancer

• Susan Modesitt, MD, FACOG, FACS

11:30 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

• All speakers

11:45 AM

Lunch

Moderator:

Myeloma

12:30 PM

Solidifying the Role of Quadruplets in NDMM

• Sagar Lonial, MD, FACP

12:45 PM

DEBATE
BCMA vs GPRC5D as Targets for Multiple Myeloma

• Ajay K. Nooka, MD, MPH, FACP
• vs
• Nisha Joseph, MD

1:05 PM

When to Use Bispecific Antibodies and CARTs in MM

• Maddhav V. Dhodapkar, MBBS

1:20 PM

DEBATE
Transplant vs No Transplant for AL Amyloidosis

• Jonathan L. Kaufman, MD
• vs
• Craig C. Hofmeister, MD, MPH

1:40 PM

Future Targets in Multiple Myeloma

• Kenneth C. Anderson, MD

1:55 PM

Patient-based Panel Discussion with EHA Highlights and Q&A

• All speakers

2:15 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP

5:00 PM

Closing Reception at Beach Club
(Name badges required for entry)

Time

Topic

Speaker

Moderator:

8:00 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FASCO

Thoracic Cancer

8:05 AM

New Treatment Options for EGFR-Mutated NSCLC

• Suresh Ramalingam, MD, FASCO

8:20 AM

DEBATE
Continuing Immunotherapy After Complete Pathologic Response with Neoadjuvant Therapy

• Conor Steuer, MD
• vs
• Jennifer Carlisle, MD

8:40 AM

Adjuvant Targeted Therapy in NSCLC

• Jennifer Carlisle, MD

8:55 AM

Stage III NSCLC Updates

• Sibo Tian, MD

9:10 AM

Defining Resistance After Front-Line Immunotherapy and Emerging Strategies for Treatment in Advanced NSCLC

• Ticiana Leal, MD

9:25 AM

Emerging Immunotherapy Strategies for SCLC

• Fatemeh Ardeshir, MD, MSc

9:40 AM

Financial Toxicity of Targeted and Immunotherapy for Lung Cancer

• Fadlo Khuri, MD

9:55 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

• All speakers

10:15 AM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP
• Suresh Ramalingam, MD, FASCO